Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial

被引：94

作者：

Sharretts, John ^{[1
]}

Galescu, Ovidiu ^{[1
]}

Gomatam, Shanti ^{[1
]}

Andraca-Carrera, Eugenio ^{[1
]}

Hampp, Christian ^{[1
]}

Yanoff, Lisa ^{[1
]}

机构：

[1] US FDA, Silver Spring, MD 20993 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 11期

关键词：

D O I：

10.1056/NEJMp2003873

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In early 2020, the FDA requested that the manufacturer of lorcaserin voluntarily withdraw the drug from the market because of a signal of increased cancer risk. The FDA concluded that the drug's benefits don't outweigh its risks for any identifiable patient population.

引用

页码：1000 / 1002

页数：3

共 5 条

[1]

[Anonymous], 2001, SURG GEN CALL ACT PR

[2] EFFECT OF DEGREE OF WEIGHT-LOSS BENEFITS [J].

BLACKBURN, G .

OBESITY RESEARCH, 1995, 3 :S211-S216

[3] Cardiovascular Safety of Lorcaserin in Overweigh or Obese Patients [J].

Bohula, E. A. ;

Wiviott, S. D. ;

McGuire, D. K. ;

Inzucchi, S. E. ;

Kuder, J. ;

Im, K. A. ;

Fanola, C. L. ;

Qamar, A. ;

Brown, C. ;

Budaj, A. ;

Garcia-Castillo, A. ;

Gupta, M. ;

Leiter, L. A. ;

Weissman, N. J. ;

White, H. D. ;

Patel, T. ;

Francis, B. ;

Miao, W. ;

Perdomo, C. ;

Dhadda, S. ;

Bonaca, M. P. ;

Ruff, C. T. ;

Keech, A. C. ;

Smith, S. R. ;

Sabatine, M. S. ;

Scirica, B. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (12) :1107-1117

[4] The FDA's Assessment of Two Drugs for Chronic Weight Management [J].

Colman, Eric ;

Golden, Julie ;

Roberts, Mary ;

Egan, Amy ;

Weaver, Joyce ;

Rosebraugh, Curtis .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (17) :1577-1579

[5]

Food and Drug Administration, 2012, SUMM MIN END MET DRU

← 1 →